biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Post by BearDownAZon Feb 17, 2017 11:47am

229 Views

Post# 25861421

Armagen reports early positive Phase II data for AGT-181

Let's try that again.

Trial shows ArmaGen biologic improves cognition in Hurler syndrome patients

I can see this being interpreted both ways. Positive: Proof of concept that trojan horse technologies yield positive clinical data for LSD programs in humans. Negative: BiOasis is not at the same clinical stage as Armagen. I'm curious for others thoughts on this.

BearDownAZ

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload